Neoadjuvant Chemotherapy Enables Pregnancy Continuation in Cervical Cancer

This small retrospective series characterizes the toxicity, surgical morbidity, and neonatal outcomes of paclitaxel-carboplatin neoadjuvant chemotherapy bridging to cesarean radical hysterectomy in pregnant cervical cancer patients, informing supportive-care and dosing decisions in a rare clinical scenario.

📅 Journal publication: Aug 2026 · Last updated: Oct 8, 2026

paclitaxelcarboplatinneoadjuvant chemotherapycervical cancerpregnancycesarean radical hysterectomygynecologic oncologyretrospective cohortplatinum-taxane Oncology Pharmacy

Also in Women's Health / Reproductive

Background Information

Innovative cervical cancer treatment preserves pregnancy in cancer patients.

Managing cervical cancer during pregnancy poses challenges for maternal and neonatal outcomes. Neoadjuvant paclitaxel-carboplatin chemotherapy followed by cesarean radical hysterectomy allowed pregnancy continuation with no cancer recurrence over a 62-month median follow-up. While this study shows promising neonatal and oncologic outcomes, the small sample size and retrospective design limit generalizability. This treatment approach may be feasible for pregnant patients with cervical cancer looking to continue their pregnancy.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Kang OJ, Koh JH, Lee SW, Park JY, Lee MY, Chung JH, Won HS, Kim DY

Citation: Kang OJ, Koh JH, Lee SW, et al. Neoadjuvant Paclitaxel-Carboplatin Chemotherapy Followed by Cesarean Radical Hysterectomy in Pregnant Patients With Cervical Cancer: Obstetric, Neonatal, and Surgical Outcomes. The journal of obstetrics and gynaecology research. 2026;52(8):e70403. doi:10.1111/jog.70403

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →